NimBio Overview
NimBio is the developer of a non-invasive Inflammometer™ - a technology that can be part of everyday devices like smartwatches or fitness bands. The company's solution is AI-powered, non-invasive technology, it can detect the early signs of inflammation in real time before a flare begins The Inflammometer™, is a groundbreaking non-invasive technology designed to passively collect real-time data for the early detection of flares in chronic inflammatory diseases to reduce hospitalizations and complications through timely treatment optimization.
Cumulative Funding Raised Over Time ($)
$500KJan 2025
$1.4MNov 2022
$1.4MSep 2019
Latest News
growth-positive
The company has raised a total of $2 million for its non-invasive technology, helping those with Inflammatory Bowel Diseases.
NimBio has raised a total of $2 million to develop its AI-powered, non-invasive Inflammometer™ technology aimed at early detection of inflammation in patients with Inflammatory Bowel Diseases (IBD). The technology, which can be integrated into everyday devices like smartwatches, aims to predict flare-ups, potentially reducing hospitalizations by up to 50% and saving billions in healthcare costs. NimBio has formed strategic partnerships with Takeda, KU Leuven, and EIT Health to accelerate clinical validation and regulatory approval. The company plans to enter the market in 2026, focusing on hospitals, pharma companies, and digital health platforms.
growth-positive
NimBio is among the thirty most promising life science and healthtech start-ups in Europe!
NimBio has been recognized as one of the thirty most promising life science and healthtech start-ups in Europe, having been selected as a semifinalist in the 9th Edition of the EIT Health Catapult competition. This accolade follows their success in the EIT Health Open Innovation IBD Challenge. NimBios flagship product, the Inflammometer™, is a non-invasive technology aimed at early detection of flares in chronic inflammatory diseases, particularly Inflammatory Bowel Diseases (IBD). The EIT Health Catapult program offers a platform for start-ups to present their innovations to industry experts and investors, with the finals set for April 2025. The competition includes significant prizes, including a €30,000 award and in-kind support from major industry players.
growth-positive
השעון החכם שיתריע לפני התפרצות מחלות דלקתיות
Nimbio, a company founded in 2018, is developing a smart wristband designed to predict inflammatory disease flare-ups, focusing initially on Crohns and colitis. The device aims to provide non-invasive monitoring to improve patient quality of life and reduce healthcare burdens. Nimbio has completed a successful clinical trial with 26 patients and plans to expand testing. The company has raised $1.5 million from investors including eHealth Ventures and other angel investors. Nimbios business model involves a subscription fee for continuous monitoring, with plans to seek regulatory approval by 2025 and begin sales in 2026.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.37M |
| Last funding | $500K |
| Stage | Pre-Seed |
| Rounds | 3 |
| Investors | 2 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.nimbio.ai |
Locations
Ha-Tsiv'oni Street 1, Tel Mond, Israel
Photos & Videos
No files yet
NimBio Business
Business models
B2B2C
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesDigital HealthcarePatient Remote MonitoringMedical Decision SupportTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCore Technology
SensingArtificial IntelligenceMachine LearningSemiconductors & ElectronicsWearablesTags (8)
wearablenon-invasiveearly-detectioninflammatory-diseaseschronic-diseasedigital-healthcaredecision-supportremote-monitoringGeographic Markets
GlobalNimBio Financials
$1.37M
Total funding
Undisclosed
Capital raised
$500K
Last funding
Pre-Seed
Funding stage
3
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$500KJan 2025
$1.4MNov 2022
$1.4MSep 2019
Private Equity Funding
Pre-Seed
Jan 2025
$500K
eHealth Ventures
Undisclosed Round
Nov 2022
$870K
eHealth Ventures (Lead)
Seed
Sep 2019
Undisclosed
Israel Innovation Authority, eHealth Ventures
NimBio Lifecycle
Cumulative Funding Raised Over Time
$500KJan 2025
$1.4MNov 2022
$1.4MSep 2019
All Events
Pre-Seed
Jan 2025
$500K
eHealth Ventures
Undisclosed Round
Nov 2022
$870K
eHealth Ventures (Lead)
Seed
Sep 2019
Undisclosed
Israel Innovation Authority, eHealth Ventures
NimBio News
3 articles
growth-positive
The company has raised a total of $2 million for its non-invasive technology, helping those with Inflammatory Bowel Diseases.
NimBio has raised a total of $2 million to develop its AI-powered, non-invasive Inflammometer™ technology aimed at early detection of inflammation in patients with Inflammatory Bowel Diseases (IBD). The technology, which can be integrated into everyday devices like smartwatches, aims to predict flare-ups, potentially reducing hospitalizations by up to 50% and saving billions in healthcare costs. NimBio has formed strategic partnerships with Takeda, KU Leuven, and EIT Health to accelerate clinical validation and regulatory approval. The company plans to enter the market in 2026, focusing on hospitals, pharma companies, and digital health platforms.
growth-positive
NimBio is among the thirty most promising life science and healthtech start-ups in Europe!
NimBio has been recognized as one of the thirty most promising life science and healthtech start-ups in Europe, having been selected as a semifinalist in the 9th Edition of the EIT Health Catapult competition. This accolade follows their success in the EIT Health Open Innovation IBD Challenge. NimBios flagship product, the Inflammometer™, is a non-invasive technology aimed at early detection of flares in chronic inflammatory diseases, particularly Inflammatory Bowel Diseases (IBD). The EIT Health Catapult program offers a platform for start-ups to present their innovations to industry experts and investors, with the finals set for April 2025. The competition includes significant prizes, including a €30,000 award and in-kind support from major industry players.
growth-positive
השעון החכם שיתריע לפני התפרצות מחלות דלקתיות
Nimbio, a company founded in 2018, is developing a smart wristband designed to predict inflammatory disease flare-ups, focusing initially on Crohns and colitis. The device aims to provide non-invasive monitoring to improve patient quality of life and reduce healthcare burdens. Nimbio has completed a successful clinical trial with 26 patients and plans to expand testing. The company has raised $1.5 million from investors including eHealth Ventures and other angel investors. Nimbios business model involves a subscription fee for continuous monitoring, with plans to seek regulatory approval by 2025 and begin sales in 2026.
Investment
NimBio Team
Yehuda Chowers
CMO
Employee Info
| Employees (range) | 1-10 |
| Exact count | 5 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
NimBio Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Yotam Maman |
| Registrar ID | 515919009 |
| Creator | Tal Atarot |
| Creator email | tal.atarot@nimbio.ai |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2025-06-10T00:00:00.000Z |
| Created | 2019-09-18T00:00:00.000Z |
| Claimed | Yes |